Merck drafts Golic to discuss low blood sugar

Share this article:

Defensive tackle-turned-sports radio talker Mike Golic has signed on to Merck and the American College of Endocrinology's Blood Sugar Basics awareness campaign, which emphasizes the importance of blood sugar control for people with type 2 diabetes.

The Emmy-winning Golic, who played with the Houston Oilers, Philadelphia Eagles and Miami Dolphins before turning to radio, is co-host of ESPN Radio's Mike & Mike in the Morning, which reaches 98 million American homes every morning. The 48-year-old has type 2 diabetes and experienced episodes of low blood sugar during gym workouts that went undiagnosed for a time as, acculturated to pushing past the pain, Golic ignored the warning signs.

Merck's diabetes products include Januvia, which is indicated for lowering blood sugar in adults with type 2 diabetes, and its metformin-added variant Janumet. Neither is associated with the Blood Sugar Basics program, which was developed by the American College of Endocrinology (ACE) with support from the drugmaker.

ACE launched the website in 2009, and the portal is being updated next month with a series of videos featuring Golic. Other tools that have recently been added to the site include videos of a type 2 diabetes patient and ACE physician, downloadable blood-sugar trackers and other information about managing the disease.
Share this article:

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro